Self-Reported Sedation Profile of Quetiapine Extended-Release and Quetiapine Immediate-Release During 6-Day Initial Dose Escalation in Bipolar Depression: A Multicenter, Randomized, Double-Blind, Phase IV Study

Clinical Therapeutics

Volumn 34, Issue 11, 2012, Pages 2202-2211

  Riesenberg, Robert A ^a   Baldytcheva, Irina ^b   Datto, Catherine ^b  

^a Atlanta Center for Medical Research   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; QUETIAPINE;

ADULT; AKATHISIA; ARTICLE; BEDTIME DOSAGE; BIPOLAR DEPRESSION; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CONVULSION; DEPRESSION; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; DSM-IV; EVENING DOSAGE; EXTRAPYRAMIDAL SYNDROME; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL DISCHARGE; HUMAN; HYPOTHESIS; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; POLYURIA; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RESTLESSNESS; SEDATION; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SUICIDE ATTEMPT; THIRST; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SELF REPORT; SLEEP; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WAKEFULNESS; YOUNG ADULT;

EID: 84869033567     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.09.002     Document Type: Article

References (30)

1. Figueroa C., Brecher M., Hamer-Maansson J.E., Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:199-204.
2. Kahn R.S., Schulz S.C., Palazov V.D., et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007, 68:832-842.
3. Bauer M., El-Khalili N., Datto C., et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010, 127:19-30.
4. Bandelow B., Chouinard G., Bobes J., et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder: data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010, 13:305-320.
5. Suppes T., Datto C., Minkwitz M., et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010, 121:106-115.
6. Cutler A.J., Datto C., Nordenhem A. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Clin Ther 2011, 33:1643-1658.
7. Weisler R., Joyce J.M., McGill L., et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009, 14:299-313.
8. Sanford M., Keating G.M. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs 2012, 26:435-460.
9. Datto C., Berggren L., Patel J.B., Eriksson H. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009, 31:492-502.
10. Nord M., Nyberg S., Brogren J., et al. Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol 2011, 11:1-10.
11. Seroquel (quetiapine fumarate) tablets [US prescribing information], Accessed July 6, 2012. http://www1.astrazeneca-us.com/pi/Seroquel.pdf.
12. Once-daily Seroquel XR (quetiapine fumarate) extended-release tablets [US prescribing information] Accessed July 6, 2012. http://www1.astrazeneca-us.com/pi/seroquelxr.pdf.
13. Declaration of Helsinki. BMJ 1996, 313:1448-1449. World Medical Organization.
14. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use Accessed July 6, 2012. http://ichgcp.net/.
15. Bond A., Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974, 47:211-218.
16. Posner K., Oquendo M.A., Gould M., et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 2007, 164:1035-1043.
17. Simpson G.N., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970, 212(Suppl 44):11-19.
18. ECDEU Assessment Manual for Psychopharmacology. Revised 1976, US Department of Health, Education, and Welfare, Washington, DC. W. Guy (Ed.).
19. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676.
20. Atkinson M.J., Sinha A., Hass S.L., et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004, 2:12.
21. Howell D.C. Statistical Methods for Psychology 2009, Wadsworth Cengage Learning, Melbourne, Australia. 7th ed.
22. Mallinckrodt C.H., Sanger T.M., Dubé S., et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 2003, 53:754-760.
23. Calabrese J.R., Keck P.E., Macfadden W., et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162:1351-1360.
24. Thase M.E., Macfadden W., Weisler R.H., et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26:600-609.
25. McElroy S.L., Weisler R.H., Chang W., et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010, 71:163-174.
26. Young A.H., McElroy S.L., Bauer M., et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010, 71:150-162.
27. Gao K., Ganocy S.J., Gajwani P., et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008, 69:302-309.
28. Miller D.D. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004, 6(Suppl 2):3-7.
29. McIntyre R.S., Konarski J.Z. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005, 66(Suppl 3):28-36.
30. Masand P.S., Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 2006, 1:47-56.